- Phase 1
- Phase 2
- Phase 3
1Confirmatory Phase 3 trial. PIXUVRI® has conditional approval in the E.U. The benefit of PIXUVRI® treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy.
You have selected a link to a third-party website. This link is provided solely as a convenience to you and not as an endorsement by CTI BioPharma of such third-party website. CTI BioPharma is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.Continue to the Requested Site